Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Investors weren’t buying the dip en masse this time. Novo’s ADRs were down 3.5% to $52.04 in premarket trading Wednesday.

That pundit was HSBC's Rajesh Kumar, who downgraded his recommendation on Novo Nordisk that morning. Image source: . Kumar ...

Shares in Novo Nordisk fell as much as 6% on Friday to their lowest since August 2021, extending recent losses to wipe out ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

(Reuters) -Shares in Wegovy maker Novo Nordisk fell around 4% on Friday to their lowest since August 2021, after U.S.

Analysts say this approval could significantly expand Alhemo's market potential. The hemophilia space is becoming ...

Novo Nordisk stock drops 20%, but strong fundamentals, growth segments, and R&D pipeline make it an undervalued opportunity.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.